Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to $4.5 million.

  • Inhibikase Therapeutics' Share-based Compensation rose 295707.59% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.7 million, marking a year-over-year increase of 517212.05%. This contributed to the annual value of $8.1 million for FY2024, which is 152764.16% up from last year.
  • Latest data reveals that Inhibikase Therapeutics reported Share-based Compensation of $4.5 million as of Q3 2025, which was up 295707.59% from $4.2 million recorded in Q2 2025.
  • In the past 5 years, Inhibikase Therapeutics' Share-based Compensation ranged from a high of $7.9 million in Q4 2024 and a low of $30697.0 during Q2 2024
  • In the last 5 years, Inhibikase Therapeutics' Share-based Compensation had a median value of $132767.0 in 2022 and averaged $1.1 million.
  • Per our database at Business Quant, Inhibikase Therapeutics' Share-based Compensation tumbled by 7915.34% in 2022 and then soared by 1361059.71% in 2025.
  • Quarter analysis of 5 years shows Inhibikase Therapeutics' Share-based Compensation stood at $265850.0 in 2021, then plummeted by 62.25% to $100363.0 in 2022, then rose by 21.81% to $122249.0 in 2023, then surged by 6369.14% to $7.9 million in 2024, then plummeted by 42.78% to $4.5 million in 2025.
  • Its Share-based Compensation stands at $4.5 million for Q3 2025, versus $4.2 million for Q2 2025 and $2.0 million for Q1 2025.